Fadi is a Primary Investigator within the Gene Regulation Observatory at the Broad Institute of MIT and Harvard. In this role, he and his team design/execute functional genomics screens to identify actionable targets in cancer and immunotherapy. This involves staying on the cutting edge of the newest approaches, but also devising novel applications of existing technologies. Fadi got his start in 2009, when he joined the lab of Paul Tesar PhD at Case Western Reserve University to study induced pluripotent stem cells and neuroscience. His work centered on discovering small molecules that could treat multiple sclerosis and other neurodegenerative diseases, resulting in the start-up of Convelo Therapeutics. He completed his MBA at Case Western Reserve University and PhD training at Harvard Biological and Biomedical Sciences (BBS) in the laboratory of Bradley Bernstein MD PhD, where he studied synthetic lethality targets in cancer.